PCIDB

KNApSAcK Metabolite C00039897

Metabolite

KNApSAcK Entry

id C00039897
Name Okadaic acid
CAS RN 78111-17-8
Standard InChI InChI=1S/C44H68O13/c1-25-21-34(55-44(23-25)35(46)12-11-31(54-44)24-41(6,50)40(48)49)26(2)9-10-30-14-18-43(53-30)19-15-33-39(57-43)36(47)29(5)38(52-33)32(45)22-28(4)37-27(3)13-17-42(56-37)16-7-8-20-51-42/h9-10,23,26-28,30-39,45-47,50H,5,7-8,11-22,24H2,1-4,6H3,(H,48,49)/b10-9+/t26-,27-,28+,30+,31+,32+,33-,34+,35-,36-,37+,38+,39-,41-,42+,43-,44-/m1/s1
Standard InChI (Main Layer) InChI=1S/C44H68O13/c1-25-21-34(55-44(23-25)35(46)12-11-31(54-44)24-41(6,50)40(48)49)26(2)9-10-30-14-18-43(53-30)19-15-33-39(57-43)36(47)29(5)38(52-33)32(45)22-28(4)37-27(3)13-17-42(56-37)16-7-8-20-51-42/h9-10,23,26-28,30-39,45-47,50H,5,7-8,11-22,24H2,1-4,6H3,(H,48,49)

Cluster

Phytochemical cluster
KCF-S cluster No. 3072

Link

ChEMBL

By standard InChI CHEMBL280487
By standard InChI Main Layer CHEMBL280487 CHEMBL158524 CHEMBL1269053 CHEMBL1454935 CHEMBL1613688 CHEMBL1728497 CHEMBL2006105 CHEMBL2068811 CHEMBL2304065

KEGG

By LinkDB C01945

CTD

By CAS RN D019319

Species

Summary

Plant class

class name count

Family

family name count
Halichondriidae 2

List (2)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Halichondria melanodocia 1183870 Halichondriidae Metazoa
Halichondria oladai 6061 Halichondriidae Metazoa

Human Protein / Gene in interaction

18 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P18031 Tyrosine-protein phosphatase non-receptor type 1 Tyr CHEMBL280487 CHEMBL766691 (1) CHEMBL767326 (1)
CHEMBL767327 (1) CHEMBL767486 (1)
0 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL1728497 CHEMBL1738132 (1)
7 / 44
Q99700 Ataxin-2 Unclassified protein CHEMBL1728497 CHEMBL2114784 (1)
1 / 1
P49798 Regulator of G-protein signaling 4 Unclassified protein CHEMBL1454935 CHEMBL1794499 (1)
2 / 0
Q15172 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform Protein phosphatase regulatory subunit CHEMBL280487 CHEMBL766692 (1)
0 / 0
P37840 Alpha-synuclein Unclassified protein CHEMBL1728497 CHEMBL2354282 (1)
4 / 2
O75688 Protein phosphatase 1B Ser_Thr CHEMBL158524 CHEMBL767316 (1)
0 / 0
P84022 Mothers against decapentaplegic homolog 3 Unclassified protein CHEMBL1728497 CHEMBL1794584 (1)
2 / 0
O75496 Geminin Unclassified protein CHEMBL1728497 CHEMBL2114843 (1)
0 / 0
P63092 Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Other membrane protein CHEMBL1728497 CHEMBL2114817 (1)
7 / 3
P36873 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit Ser_Thr CHEMBL280487 CHEMBL804804 (1) CHEMBL806666 (1)
CHEMBL806667 (1) CHEMBL806668 (1)
CHEMBL806669 (1) CHEMBL806670 (1)
CHEMBL806671 (1) CHEMBL806672 (1)
CHEMBL806673 (1) CHEMBL798973 (1)
CHEMBL798976 (1) CHEMBL798978 (1)
CHEMBL798979 (1) CHEMBL878022 (1)
CHEMBL798980 (1)
0 / 0
Q96QE3 ATPase family AAA domain-containing protein 5 Unclassified protein CHEMBL1728497 CHEMBL1738588 (1)
0 / 0
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL280487 CHEMBL2038278 (1)
0 / 1
Q9UNA4 DNA polymerase iota Enzyme CHEMBL1728497 CHEMBL1794483 (1)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL1613688 CHEMBL1614250 (1)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL1728497 CHEMBL1738184 (1)
0 / 0
P67775 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Ser_Thr CHEMBL158524 CHEMBL768151 (1)
0 / 0
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic Enzyme CHEMBL1728497 CHEMBL2354311 (1)
1 / 0

CTD interaction (145)

compound gene gene name gene description interaction interaction type form reference
pmid
D019319 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of AKT1 protein] decreases phosphorylation
/ decreases reaction
protein 16059913
D019319 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Okadaic Acid inhibits the reaction [arsenic trioxide promotes the reaction [AKT1 protein binds to PPP2CA protein]] affects binding
/ decreases reaction
/ increases reaction
protein 21655183
D019319 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Okadaic Acid inhibits the reaction [arsenic trioxide results in decreased phosphorylation of AKT1 protein] decreases phosphorylation
/ decreases reaction
protein 21655183
D019319 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Okadaic Acid inhibits the reaction [bortezomib results in decreased expression of AKT1 protein modified form] decreases expression
/ decreases reaction
protein 19261616
D019319 226 ALDOA
ALDA
GSD12
aldolase A, fructose-bisphosphate (EC:4.1.2.13) Okadaic Acid results in decreased expression of ALDOA protein decreases expression
protein 19397276
D019319 498 ATP5A1
ATP5A
ATP5AL2
ATPM
MC5DN4
MOM2
OMR
ORM
hATP1
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle Okadaic Acid results in decreased expression of ATP5A1 protein decreases expression
protein 19397276
D019319 513 ATP5D
ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit (EC:3.6.1.14) [Okadaic Acid co-treated with gambierol] results in increased expression of ATP5D protein affects cotreatment
/ increases expression
protein 19397276
D019319 513 ATP5D
ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit (EC:3.6.1.14) Okadaic Acid results in decreased expression of ATP5D protein decreases expression
protein 19397276
D019319 581 BAX
BCL2L4
BCL2-associated X protein Okadaic Acid affects the localization of BAX protein affects localization
protein 19084044
D019319 581 BAX
BCL2L4
BCL2-associated X protein Okadaic Acid results in decreased expression of BAX protein decreases expression
protein 18937299
D019319 581 BAX
BCL2L4
BCL2-associated X protein Okadaic Acid results in increased cleavage of and results in increased activity of BAX protein increases activity
/ increases cleavage
protein 19084044
D019319 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Okadaic Acid results in decreased expression of BCL2 protein decreases expression
protein 18937299
D019319 27101 CACYBP
GIG5
RP1-102G20.6
S100A6BP
SIP
calcyclin binding protein Okadaic Acid results in decreased expression of CACYBP protein decreases expression
protein 19397276
D019319 843 CASP10
ALPS2
FLICE2
MCH4
caspase 10, apoptosis-related cysteine peptidase (EC:3.4.22.63) Okadaic Acid results in increased cleavage of and results in increased activity of CASP10 protein increases activity
/ increases cleavage
protein 19084044
D019319 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 19084044
D019319 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 19084044
D019319 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Okadaic Acid results in increased cleavage of and results in increased activity of CASP3 protein increases activity
/ increases cleavage
protein 19084044
D019319 840 CASP7
CASP-7
CMH-1
ICE-LAP3
LICE2
MCH3
caspase 7, apoptosis-related cysteine peptidase (EC:3.4.22.60) Okadaic Acid results in increased cleavage of and results in increased activity of CASP7 protein increases activity
/ increases cleavage
protein 19084044
D019319 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP8 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 19084044
D019319 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Okadaic Acid results in increased cleavage of and results in increased activity of CASP8 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 19084044
D019319 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) Okadaic Acid results in increased cleavage of and results in increased activity of CASP8 protein increases activity
/ increases cleavage
protein 19084044
D019319 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Okadaic Acid results in increased cleavage of and results in increased activity of CASP9 protein increases activity
/ increases cleavage
protein 19084044
D019319 8900 CCNA1
cyclin A1 Okadaic Acid affects the expression of CCNA1 mRNA affects expression
mRNA 21512803
D019319 9133 CCNB2
HsT17299
cyclin B2 Okadaic Acid affects the expression of CCNB2 mRNA affects expression
mRNA 21512803
D019319 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) Okadaic Acid results in decreased expression of CDK1 mRNA decreases expression
mRNA 21512803
D019319 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Okadaic Acid results in decreased expression of CDK2 mRNA decreases expression
mRNA 21512803
D019319 1072 CFL1
CFL
cofilin 1 (non-muscle) Okadaic Acid results in increased expression of CFL1 protein increases expression
protein 19397276
D019319 1080 CFTR
ABC35
ABCC7
CF
CFTR/MRP
MRP7
TNR-CFTR
dJ760C5.1
cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) Okadaic Acid results in decreased activity of CFTR protein decreases activity
protein 15936019
D019319 54927 CHCHD3
MINOS3
PPP1R22
coiled-coil-helix-coiled-coil-helix domain containing 3 Okadaic Acid results in decreased expression of CHCHD3 protein decreases expression
protein 19397276
D019319 1139 CHRNA7
CHRNA7-2
NACHRA7
cholinergic receptor, nicotinic, alpha 7 (neuronal) [[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] which results in increased uptake of Calcium] inhibits the reaction [CHRNA7 protein results in decreased susceptibility to Okadaic Acid] affects activity
/ decreases reaction
/ decreases response to substance
/ increases uptake
protein 21715663
D019319 1139 CHRNA7
CHRNA7-2
NACHRA7
cholinergic receptor, nicotinic, alpha 7 (neuronal) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid] affects binding
/ decreases reaction
/ decreases response to substance
/ increases activity
protein 21715663
D019319 1139 CHRNA7
CHRNA7-2
NACHRA7
cholinergic receptor, nicotinic, alpha 7 (neuronal) JAK2 protein affects the reaction [[PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid] affects binding
/ affects reaction
/ decreases response to substance
/ increases activity
protein 21715663
D019319 1139 CHRNA7
CHRNA7-2
NACHRA7
cholinergic receptor, nicotinic, alpha 7 (neuronal) [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 1139 CHRNA7
CHRNA7-2
NACHRA7
cholinergic receptor, nicotinic, alpha 7 (neuronal) [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 1139 CHRNA7
CHRNA7-2
NACHRA7
cholinergic receptor, nicotinic, alpha 7 (neuronal) [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] affects binding
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 21715663
D019319 1139 CHRNA7
CHRNA7-2
NACHRA7
cholinergic receptor, nicotinic, alpha 7 (neuronal) [PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid affects binding
/ decreases response to substance
/ increases activity
protein 21715663
D019319 1141 CHRNB2
EFNL3
nAChRB2
cholinergic receptor, nicotinic, beta 2 (neuronal) 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid] affects binding
/ decreases reaction
/ decreases response to substance
/ increases activity
protein 21715663
D019319 1141 CHRNB2
EFNL3
nAChRB2
cholinergic receptor, nicotinic, beta 2 (neuronal) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid] affects binding
/ decreases reaction
/ decreases response to substance
/ increases activity
protein 21715663
D019319 1141 CHRNB2
EFNL3
nAChRB2
cholinergic receptor, nicotinic, beta 2 (neuronal) [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 1141 CHRNB2
EFNL3
nAChRB2
cholinergic receptor, nicotinic, beta 2 (neuronal) [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 1141 CHRNB2
EFNL3
nAChRB2
cholinergic receptor, nicotinic, beta 2 (neuronal) [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] affects binding
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 21715663
D019319 1141 CHRNB2
EFNL3
nAChRB2
cholinergic receptor, nicotinic, beta 2 (neuronal) [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid affects binding
/ decreases response to substance
/ increases activity
protein 21715663
D019319 1141 CHRNB2
EFNL3
nAChRB2
cholinergic receptor, nicotinic, beta 2 (neuronal) Calcium affects the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid] affects binding
/ affects reaction
/ decreases response to substance
/ increases activity
protein 21715663
D019319 1207 CLNS1A
CLCI
CLNS1B
ICln
chloride channel, nucleotide-sensitive, 1A Okadaic Acid results in decreased expression of CLNS1A protein decreases expression
protein 19397276
D019319 1312 COMT
catechol-O-methyltransferase (EC:2.1.1.6) [Okadaic Acid co-treated with gambierol] results in decreased expression of COMT protein affects cotreatment
/ decreases expression
protein 19397276
D019319 1312 COMT
catechol-O-methyltransferase (EC:2.1.1.6) Okadaic Acid results in decreased expression of COMT protein decreases expression
protein 19397276
D019319 1387 CREBBP
CBP
KAT3A
RSTS
CREB binding protein (EC:2.3.1.48) Okadaic Acid results in increased phosphorylation of CREBBP protein increases phosphorylation
protein 16059639
D019319 1499 CTNNB1
CTNNB
MRD19
armadillo
catenin (cadherin-associated protein), beta 1, 88kDa Okadaic Acid results in increased phosphorylation of CTNNB1 protein increases phosphorylation
protein 16878161
D019319 1545 CYP1B1
CP1B
CYPIB1
GLC3A
P4501B1
cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) Okadaic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] increases expression
/ increases reaction
mRNA 10696073
D019319 1601 DAB2
DOC-2
DOC2
Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) Okadaic Acid affects the phosphorylation of DAB2 protein affects phosphorylation
protein 12881709
D019319 10521 DDX17
P72
RH70
DEAD (Asp-Glu-Ala-Asp) box helicase 17 (EC:3.6.4.13) Okadaic Acid results in decreased expression of DDX17 protein decreases expression
protein 19397276
D019319 11034 DSTN
ACTDP
ADF
bA462D18.2
destrin (actin depolymerizing factor) Okadaic Acid results in decreased expression of DSTN protein decreases expression
protein 19397276
D019319 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Okadaic Acid results in increased degradation of ESR1 mRNA] decreases reaction
/ increases degradation
mRNA 15965230
D019319 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Okadaic Acid inhibits the reaction [Linoleic Acids, Conjugated results in decreased phosphorylation of ESR1 protein] decreases phosphorylation
/ decreases reaction
protein 19800873
D019319 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Okadaic Acid results in decreased expression of ESR1 protein decreases expression
protein 15965230
D019319 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 Okadaic Acid results in increased degradation of and results in decreased expression of ESR1 mRNA decreases expression
/ increases degradation
mRNA 15965230
D019319 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog Okadaic Acid results in increased expression of FOS mRNA increases expression
mRNA 7963561
D019319 2739 GLO1
GLOD1
GLYI
glyoxalase I (EC:4.4.1.5) [Okadaic Acid co-treated with gambierol] results in decreased expression of GLO1 protein affects cotreatment
/ decreases expression
protein 19397276
D019319 2739 GLO1
GLOD1
GLYI
glyoxalase I (EC:4.4.1.5) Okadaic Acid results in decreased expression of GLO1 protein decreases expression
protein 19397276
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein] decreases reaction
/ increases expression
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form] decreases reaction
/ increases expression
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] decreases activity
/ decreases reaction
/ increases phosphorylation
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] which results in decreased susceptibility to Okadaic Acid decreases activity
/ decreases response to substance
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) Okadaic Acid results in increased expression of GSK3B protein increases expression
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) Okadaic Acid results in increased expression of GSK3B protein modified form increases expression
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased expression of GSK3B protein modified form] affects binding
/ decreases reaction
/ increases activity
/ increases expression
protein 21715663
D019319 3315 HSPB1
CMT2F
HMN2B
HS.76067
HSP27
HSP28
Hsp25
SRP27
heat shock 27kDa protein 1 Okadaic Acid affects the expression of HSPB1 protein modified form affects expression
protein 19397276
D019319 3315 HSPB1
CMT2F
HMN2B
HS.76067
HSP27
HSP28
Hsp25
SRP27
heat shock 27kDa protein 1 [Okadaic Acid co-treated with gambierol] affects the expression of HSPB1 protein modified form affects cotreatment
/ affects expression
protein 19397276
D019319 3315 HSPB1
CMT2F
HMN2B
HS.76067
HSP27
HSP28
Hsp25
SRP27
heat shock 27kDa protein 1 [Okadaic Acid co-treated with gambierol] results in increased expression of HSPB1 protein affects cotreatment
/ increases expression
protein 19397276
D019319 3315 HSPB1
CMT2F
HMN2B
HS.76067
HSP27
HSP28
Hsp25
SRP27
heat shock 27kDa protein 1 Okadaic Acid results in decreased expression of HSPB1 protein decreases expression
protein 19397276
D019319 3315 HSPB1
CMT2F
HMN2B
HS.76067
HSP27
HSP28
Hsp25
SRP27
heat shock 27kDa protein 1 Okadaic Acid results in increased expression of HSPB1 protein increases expression
protein 19397276
D019319 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta Okadaic Acid inhibits the reaction [IL1B protein results in decreased phosphorylation of RELA protein] decreases phosphorylation
/ decreases reaction
protein 11591705
D019319 3717 JAK2
JTK10
THCYT3
Janus kinase 2 (EC:2.7.10.2) JAK2 protein affects the reaction [[PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in decreased susceptibility to Okadaic Acid] affects binding
/ affects reaction
/ decreases response to substance
/ increases activity
protein 21715663
D019319 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Okadaic Acid inhibits the reaction [Tretinoin results in decreased phosphorylation of JUN protein] decreases phosphorylation
/ decreases reaction
protein 16052510
D019319 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Okadaic Acid results in increased activity of MAPK1 protein increases activity
protein 19716839
D019319 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Okadaic Acid results in increased activity of MAPK3 protein increases activity
protein 19716839
D019319 5598 MAPK7
BMK1
ERK4
ERK5
PRKM7
mitogen-activated protein kinase 7 (EC:2.7.11.24) Okadaic Acid results in increased phosphorylation of and results in increased activity of MAPK7 protein increases activity
/ increases phosphorylation
protein 19716839
D019319 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau [5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] affects binding
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 21715663
D019319 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau [N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea results in decreased activity of GSK3B protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] decreases activity
/ decreases reaction
/ increases phosphorylation
protein 21715663
D019319 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau [Okadaic Acid co-treated with immunomycin] results in increased phosphorylation of MAPT protein affects cotreatment
/ increases phosphorylation
protein 7723735
D019319 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau Okadaic Acid results in increased phosphorylation of MAPT protein increases phosphorylation
protein 7723735
21715663
D019319 4137 MAPT
DDPAC
FTDP-17
MAPTL
MSTD
MTBT1
MTBT2
PPND
TAU
microtubule-associated protein tau [PNU-282987 binds to and results in increased activity of CHRNA7 protein] inhibits the reaction [Okadaic Acid results in increased phosphorylation of MAPT protein] affects binding
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 21715663
D019319 5469 MED1
CRSP1
CRSP200
DRIP205
DRIP230
PBP
PPARBP
PPARGBP
RB18A
TRAP220
TRIP2
mediator complex subunit 1 [1,25-dihydroxyvitamin D co-treated with Okadaic Acid] promotes the reaction [VDR protein mutant form binds to MED1 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 16059639
D019319 23184 MESDC2
BOCA
MESD
mesoderm development candidate 2 Okadaic Acid results in decreased expression of MESDC2 protein decreases expression
protein 19397276
D019319 4625 MYH7
CMD1S
CMH1
MPD1
MYHCB
SPMD
SPMM
myosin, heavy chain 7, cardiac muscle, beta [Okadaic Acid co-treated with gambierol] results in increased expression of MYH7 protein modified form affects cotreatment
/ increases expression
protein 19397276
D019319 54187 NANS
SAS
N-acetylneuraminic acid synthase (EC:2.5.1.56 2.5.1.57) Okadaic Acid results in decreased expression of NANS protein decreases expression
protein 19397276
D019319 9611 NCOR1
N-CoR
N-CoR1
TRAC1
hN-CoR
nuclear receptor corepressor 1 Okadaic Acid results in decreased activity of NCOR1 protein decreases activity
protein 17312396
D019319 9611 NCOR1
N-CoR
N-CoR1
TRAC1
hN-CoR
nuclear receptor corepressor 1 [Tretinoin co-treated with Okadaic Acid] results in decreased activity of NCOR1 protein affects cotreatment
/ decreases activity
protein 17312396
D019319 4780 NFE2L2
NRF2
nuclear factor, erythroid 2-like 2 Okadaic Acid results in increased expression of NFE2L2 protein increases expression
protein 12446695
D019319 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 anethole inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]] affects binding
/ decreases reaction
/ increases activity
protein 10871845
D019319 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 evodiamine inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein] decreases reaction
/ increases activity
protein 15710601
D019319 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Fenretinide inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein] decreases reaction
/ increases activity
protein 16230421
D019319 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein] decreases reaction
/ increases activity
protein 15090542
D019319 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 Okadaic Acid inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]] affects binding
/ decreases reaction
/ increases activity
protein 9973483
D019319 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 pregna-4,17-diene-3,16-dione inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein] decreases reaction
/ increases activity
protein 15322087
D019319 4790 NFKB1
EBP-1
KBF1
NF-kB1
NF-kappa-B
NF-kappaB
NFKB-p105
NFKB-p50
NFkappaB
p105
p50
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 zerumbone inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]] affects binding
/ decreases reaction
/ increases activity
protein 16007145
D019319 4830 NME1
AWD
GAAD
NB
NBS
NDKA
NDPK-A
NDPKA
NM23
NM23-H1
NME/NM23 nucleoside diphosphate kinase 1 (EC:2.7.4.6) [Okadaic Acid co-treated with gambierol] results in decreased expression of NME1 protein affects cotreatment
/ decreases expression
protein 19397276
D019319 4830 NME1
AWD
GAAD
NB
NBS
NDKA
NDPK-A
NDPKA
NM23
NM23-H1
NME/NM23 nucleoside diphosphate kinase 1 (EC:2.7.4.6) Okadaic Acid results in decreased expression of NME1 protein decreases expression
protein 19397276
D019319 8856 NR1I2
BXR
ONR1
PAR
PAR1
PAR2
PARq
PRR
PXR
SAR
SXR
nuclear receptor subfamily 1, group I, member 2 Okadaic Acid results in increased activity of NR1I2 protein increases activity
protein 22206814
D019319 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Okadaic Acid inhibits the reaction [Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]] decreases reaction
/ increases cleavage
/ increases reaction
protein 16059913
D019319 5093 PCBP1
HNRPE1
HNRPX
hnRNP-E1
hnRNP-X
poly(rC) binding protein 1 [Okadaic Acid co-treated with gambierol] results in decreased expression of PCBP1 protein affects cotreatment
/ decreases expression
protein 19397276
D019319 5093 PCBP1
HNRPE1
HNRPX
hnRNP-E1
hnRNP-X
poly(rC) binding protein 1 Okadaic Acid results in decreased expression of PCBP1 protein decreases expression
protein 19397276
D019319 5110 PCMT1
PIMT
protein-L-isoaspartate (D-aspartate) O-methyltransferase (EC:2.1.1.77) Okadaic Acid results in decreased expression of PCMT1 protein decreases expression
protein 19397276
D019319 3651 PDX1
GSF
IDX-1
IPF1
IUF1
MODY4
PDX-1
STF-1
pancreatic and duodenal homeobox 1 Okadaic Acid inhibits the reaction [Glucose affects the localization of PDX1 protein] affects localization
/ decreases reaction
protein 11574405
D019319 5223 PGAM1
PGAM-B
PGAMA
phosphoglycerate mutase 1 (brain) (EC:3.1.3.13 5.4.2.4 5.4.2.11) [Okadaic Acid co-treated with gambierol] results in decreased expression of PGAM1 protein affects cotreatment
/ decreases expression
protein 19397276
D019319 5241 PGR
NR3C3
PR
progesterone receptor Okadaic Acid results in decreased expression of PGR mRNA decreases expression
mRNA 15965230
D019319 5241 PGR
NR3C3
PR
progesterone receptor Okadaic Acid results in decreased expression of PGR protein decreases expression
protein 15965230
D019319 5465 PPARA
NR1C1
PPAR
PPARalpha
hPPAR
peroxisome proliferator-activated receptor alpha Okadaic Acid inhibits the reaction [Nafenopin results in increased activity of PPARA protein] decreases reaction
/ increases activity
protein 18079279
D019319 5465 PPARA
NR1C1
PPAR
PPARalpha
hPPAR
peroxisome proliferator-activated receptor alpha Okadaic Acid results in increased activity of and results in increased stability of PPARA protein increases activity
/ increases stability
protein 15178457
D019319 5478 PPIA
CYPA
CYPH
peptidylprolyl isomerase A (cyclophilin A) (EC:5.2.1.8) Okadaic Acid results in decreased expression of PPIA protein decreases expression
protein 19397276
D019319 5499 PPP1CA
PP-1A
PP1A
PP1alpha
PPP1A
protein phosphatase 1, catalytic subunit, alpha isozyme (EC:3.1.3.16) Okadaic Acid inhibits the reaction [Amiloride results in decreased phosphorylation of PPP1CA protein] decreases phosphorylation
/ decreases reaction
protein 16059913
D019319 5515 PPP2CA
PP2Ac
PP2CA
PP2Calpha
RP-C
protein phosphatase 2, catalytic subunit, alpha isozyme (EC:3.1.3.16) Okadaic Acid inhibits the reaction [arsenic trioxide promotes the reaction [AKT1 protein binds to PPP2CA protein]] affects binding
/ decreases reaction
/ increases reaction
protein 21655183
D019319 5515 PPP2CA
PP2Ac
PP2CA
PP2Calpha
RP-C
protein phosphatase 2, catalytic subunit, alpha isozyme (EC:3.1.3.16) Okadaic Acid results in decreased activity of PPP2CA protein decreases activity
protein 15965230
22205926
D019319 5515 PPP2CA
PP2Ac
PP2CA
PP2Calpha
RP-C
protein phosphatase 2, catalytic subunit, alpha isozyme (EC:3.1.3.16) [Okadaic Acid results in decreased activity of PPP2CA protein] which results in decreased susceptibility to Dexamethasone decreases activity
/ decreases response to substance
protein 22205926
D019319 5518 PPP2R1A
PP2A-Aalpha
PP2AAALPHA
PR65A
protein phosphatase 2, regulatory subunit A, alpha (EC:3.1.3.16) Okadaic Acid results in increased expression of PPP2R1A protein increases expression
protein 18937299
D019319 25824 PRDX5
ACR1
AOEB166
B166
PLP
PMP20
PRDX6
PRXV
prx-V
peroxiredoxin 5 (EC:1.11.1.15) [Okadaic Acid co-treated with gambierol] results in decreased expression of PRDX5 protein affects cotreatment
/ decreases expression
protein 19397276
D019319 25824 PRDX5
ACR1
AOEB166
B166
PLP
PMP20
PRDX6
PRXV
prx-V
peroxiredoxin 5 (EC:1.11.1.15) Okadaic Acid results in decreased expression of PRDX5 protein decreases expression
protein 19397276
D019319 9588 PRDX6
1-Cys
AOP2
NSGPx
PRX
aiPLA2
p29
peroxiredoxin 6 (EC:1.11.1.9 1.11.1.15) [Okadaic Acid co-treated with gambierol] results in decreased expression of PRDX6 protein affects cotreatment
/ decreases expression
protein 19397276
D019319 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Okadaic Acid inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of RB1 protein] decreases phosphorylation
/ decreases reaction
protein 12621062
D019319 5933 RBL1
CP107
PRB1
p107
retinoblastoma-like 1 (p107) Okadaic Acid inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of RBL1 protein] decreases phosphorylation
/ decreases reaction
protein 12621062
D019319 5934 RBL2
P130
Rb2
retinoblastoma-like 2 (p130) Okadaic Acid inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of RBL2 protein] decreases phosphorylation
/ decreases reaction
protein 12621062
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A anethole inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]] affects binding
/ decreases reaction
/ increases activity
protein 10871845
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A evodiamine inhibits the reaction [Okadaic Acid results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 15710601
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Fenretinide inhibits the reaction [Okadaic Acid results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 16230421
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 15090542
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Okadaic Acid inhibits the reaction [A 771726 results in increased activity of [NFKB1 protein binds to RELA protein]] affects binding
/ decreases reaction
/ increases activity
protein 9973483
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Okadaic Acid inhibits the reaction [IL1B protein results in decreased phosphorylation of RELA protein] decreases phosphorylation
/ decreases reaction
protein 11591705
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A Okadaic Acid results in increased phosphorylation of RELA protein increases phosphorylation
protein 11591705
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A pregna-4,17-diene-3,16-dione inhibits the reaction [Okadaic Acid results in increased activity of RELA protein] decreases reaction
/ increases activity
protein 15322087
D019319 5970 RELA
NFKB3
p65
v-rel avian reticuloendotheliosis viral oncogene homolog A zerumbone inhibits the reaction [Okadaic Acid results in increased activity of [NFKB1 protein binds to RELA protein]] affects binding
/ decreases reaction
/ increases activity
protein 16007145
D019319 6206 RPS12
S12
ribosomal protein S12 Okadaic Acid results in decreased expression of RPS12 protein decreases expression
protein 19397276
D019319 6256 RXRA
NR2B1
retinoid X receptor, alpha [Tretinoin co-treated with alpha-Tocopherol co-treated with Okadaic Acid] results in decreased phosphorylation of RXRA protein affects cotreatment
/ decreases phosphorylation
protein 15225641
D019319 6406 SEMG1
CT103
SEMG
SGI
dJ172H20.2
semenogelin I Okadaic Acid results in decreased expression of SEMG1 protein decreases expression
protein 19397276
D019319 6647 SOD1
ALS
ALS1
IPOA
SOD
hSod1
homodimer
superoxide dismutase 1, soluble (EC:1.15.1.1) Okadaic Acid results in decreased expression of SOD1 protein decreases expression
protein 19397276
D019319 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) [Okadaic Acid co-treated with gambierol] results in increased expression of SOD2 protein affects cotreatment
/ increases expression
protein 19397276
D019319 7018 TF
PRO1557
PRO2086
TFQTL1
transferrin Okadaic Acid results in decreased uptake of TF protein decreases uptake
protein 16563724
D019319 8743 TNFSF10
APO2L
Apo-2L
CD253
TL2
TRAIL
tumor necrosis factor (ligand) superfamily, member 10 Okadaic Acid inhibits the reaction [Amiloride promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]] decreases reaction
/ increases cleavage
/ increases reaction
protein 16059913
D019319 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Okadaic Acid affects the localization of TP53 protein affects localization
protein 21512803
D019319 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Okadaic Acid results in decreased expression of TP53 protein decreases expression
protein 18937299
D019319 7295 TXN
TRDX
TRX
TRX1
thioredoxin Okadaic Acid results in decreased expression of TXN protein decreases expression
protein 19397276
D019319 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor [1,25-dihydroxyvitamin D co-treated with Okadaic Acid] promotes the reaction [VDR protein mutant form binds to MED1 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 16059639
D019319 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor [1,25-dihydroxyvitamin D co-treated with Okadaic Acid] results in increased activity of VDR protein mutant form affects cotreatment
/ increases activity
protein 16059639

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (28)

OMIM preferred title UniProt
#219080 Acth-independent macronodular adrenal hyperplasia; aimah P63092
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#114500 Colorectal cancer; crc P84022
#127750 Dementia, lewy body; dlb P37840
#133239 Esophageal cancer P04637
#600274 Frontotemporal dementia; ftd P10636
#137800 Glioma susceptibility 1; glm1 O75874
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#613795 Loeys-dietz syndrome, type 3; lds3 P84022
#211980 Lung cancer P04637
#174800 Mccune-albright syndrome; mas P63092
#166350 Osseous heteroplasia, progressive; poh P63092
#260500 Papilloma of choroid plexus; cpp P04637
#168601 Parkinson disease 1, autosomal dominant; park1 P37840
#605543 Parkinson disease 4, autosomal dominant; park4 P37840
#168600 Parkinson disease, late-onset; pd P37840
#260540 Parkinson-dementia syndrome P10636
#172700 Pick disease of brain P10636
#102200 Pituitary adenoma, growth hormone-secreting P63092
#103580 Pseudohypoparathyroidism, type ia; php1a P63092
#603233 Pseudohypoparathyroidism, type ib; php1b P63092
#612462 Pseudohypoparathyroidism, type ic; php1c P63092
#604906 Schizophrenia 9; sczd9 P49798
#181500 Schizophrenia; sczd P49798
#183090 Spinocerebellar ataxia 2; sca2 Q99700
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636

KEGG DISEASE (46)

KEGG disease name UniProt
H00004 Chronic myeloid leukemia (CML) P04637 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00016 Oral cancer P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P04637 (related)
P04637 (marker)
H00018 Gastric cancer P04637 (related)
H00019 Pancreatic cancer P04637 (related)
P04637 (marker)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00022 Bladder cancer P04637 (related)
H00025 Penile cancer P04637 (related)
P04637 (marker)
H00026 Endometrial Cancer P04637 (related)
H00027 Ovarian cancer P04637 (related)
H00028 Choriocarcinoma P04637 (related)
H00029 Vulvar cancer P04637 (related)
H00031 Breast cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
H00033 Adrenal carcinoma P04637 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00042 Glioma P04637 (related)
P04637 (marker)
H00044 Cancer of the anal canal P04637 (related)
H00046 Cholangiocarcinoma P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00055 Laryngeal cancer P04637 (related)
P04637 (marker)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00057 Parkinson's disease (PD) P37840 (related)
H00066 Lewy body dementia (LBD) P37840 (related)
H00244 Pseudohypoparathyroidism P63092 (related)
H00441 Progressive osseous heteroplasia (POH) P63092 (related)
H00501 Fibrous dysplasia, polyostotic P63092 (related)
H00063 Spinocerebellar ataxia (SCA) Q99700 (related)

Diseases related to CTD interactions

5 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D005909 D019319 Glioblastoma therapeutic
17312396
D006930 D019319 Hyperalgesia marker/mechanism
therapeutic
7715785
14659528
D009410 D019319 Nerve Degeneration marker/mechanism
21715663
23335626
D057096 D019319 Shellfish Poisoning marker/mechanism
19084044
19916524
21512803
D012878 D019319 Skin Neoplasms marker/mechanism
8597533
12628509
21533367